Skip to main content
Premium Trial:

Request an Annual Quote

BD Biosciences Revenue Grows 10 Percent in Fiscal Q1 on Strong Reagent, Instrument Sales

This update serves to clarfy the fact that fourth-quarter profit increased 11.5 percent, not 40 percent as originally reported.

 

NEW YORK, Jan. 26 (GenomeWeb News) - Becton Dickinson today said that fiscal first-quarter revenue for its Biosciences division grew more than 10 percent while overall receipts at the life sciences company increased 10 percent as well.

 

Total receipts for the Biosciences unit during the three months ended Dec. 31, 2005, increased to $199.5 million from $180.8 million year over year. Around $85 million of that was from sales in the United States, representing a 12.7-percent increase in sales to that country. The remainder, or approximately $114 million, was in international sales, which represented an 8.7-percent increase in sales.

 

BD attributed the growth to strong sales of reagents and research instruments, particularly research analyzers and sorters.

 

BD said company-wide fiscal first-quarter revenue increased 10 percent to $1.4 billion, though "unfavorable" foreign-currency translations cost the firm 1 percent in lost growth.

 

Spending on R&D increased 11.7 percent in the quarter, jumping to $69.3 million from $62 million year over year, BD said.

 

The company said profits increased 11.5 percent to $217.9 million, or $.88 per basic share, from $195.4 million, or $.78 per basic share, during the same period last year.

 

BD did not break out its balance sheet for the quarter.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.